LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

LLY

749.48

-0.89%↓

JNJ

176.96

-0.68%↓

ABBV

217.85

-0.57%↓

UNH

348.05

-0.48%↓

AZN

77.88

-0.5%↓

Search

Myriad Genetics Inc

Slēgts

SektorsVeselības aprūpe

7.29 0.55

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.08

Max

7.45

Galvenie mērījumi

By Trading Economics

Ienākumi

-330M

-331M

Pārdošana

17M

213M

Peļņas marža

-155.092

Darbinieki

2,700

EBITDA

-301M

-315M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+0.69% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

276M

643M

Iepriekšējā atvēršanas cena

6.74

Iepriekšējā slēgšanas cena

7.29

Ziņu noskaņojums

By Acuity

40%

60%

154 / 371 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

Myriad Genetics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 15. sept. 22:39 UTC

Iegādes, apvienošanās, pārņemšana

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

2025. g. 15. sept. 16:43 UTC

Galvenie tirgus virzītāji

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

2025. g. 15. sept. 16:42 UTC

Galvenie tirgus virzītāji

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

2025. g. 15. sept. 16:35 UTC

Galvenie tirgus virzītāji

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 23:46 UTC

Tirgus saruna

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

2025. g. 15. sept. 23:34 UTC

Tirgus saruna

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

2025. g. 15. sept. 22:48 UTC

Tirgus saruna

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Expects Commercial Launch in 2029

2025. g. 15. sept. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

2025. g. 15. sept. 22:11 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Have Right to Exercise Option Based on Phase 3 Data

2025. g. 15. sept. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

2025. g. 15. sept. 21:16 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

2025. g. 15. sept. 21:15 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy 48,000 Net Acres in the Williston Core

2025. g. 15. sept. 21:14 UTC

Iegādes, apvienošanās, pārņemšana

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 15. sept. 19:29 UTC

Tirgus saruna

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

2025. g. 15. sept. 19:14 UTC

Tirgus saruna

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

2025. g. 15. sept. 18:16 UTC

Tirgus saruna

Gold Powers to New High -- Market Talk

2025. g. 15. sept. 18:05 UTC

Tirgus saruna

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

2025. g. 15. sept. 17:50 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 15. sept. 17:10 UTC

Tirgus saruna

S&P Expects Fed, BOC to Cut Rates -- Market Talk

2025. g. 15. sept. 16:52 UTC

Tirgus saruna

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2025. g. 15. sept. 16:20 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Myriad Genetics Inc Prognoze

Cenas mērķis

By TipRanks

0.69% augšup

Prognoze 12 mēnešiem

Vidējais 7.29 USD  0.69%

Augstākais 9 USD

Zemākais 6 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Myriad Genetics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

8 ratings

3

Pirkt

5

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

N/A / 7.55Atbalsts un pretestība

Īstermiņā

Strong Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Noskaņojums

By Acuity

154 / 371 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Myriad Genetics Inc

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
help-icon Live chat